# Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

> **NCT02117791** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1298 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Riociguat (ADEMPAS, BAY63-2521)

## Key facts

- **NCT ID:** NCT02117791
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-16
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-09-20
- **Target enrollment:** 1298 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117791, "Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02117791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*